Clinical trial
Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of…
NCT00411073 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00411073 |
|---|---|
| Title | Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart |
| Official title | A Study to Evaluate the Effect of Repeat Oral Doses of Darapladib on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Atherosclerosis |
| Intervention type | Drug |
| Interventions | Darapladib |
| Enrollment | 72 |
| Start date | Dec 1, 2006 |
| First posted | Dec 13, 2006 |
| Last update posted | Oct 28, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: